17,141 results match your criteria rcc


Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2.

Curr Issues Mol Biol 2021 Sep 6;43(2):1072-1080. Epub 2021 Sep 6.

Cancer Research Institute, Tomsk National Research Medical Center, 634050 Tomsk, Russia.

Regulation of immunity is a unique oncogenic mechanism that differs in different cancers. VHL deficient clear cell renal cell carcinomas (ccRCC) trigger the immune response resulting in cancer progression. This study aimed to investigate PD-1, PD-L1, and PD-L2 expression in ccRCC primary cancers and metastatic tissues associated with the p-VHL content, transcriptional, and growth factors expression. Read More

View Article and Full-Text PDF
September 2021

Analgesic use and the risk of renal cell carcinoma - Findings from the Consortium for the Investigation of Renal Malignancies (CONFIRM) study.

Cancer Epidemiol 2021 Sep 22;75:102036. Epub 2021 Sep 22.

Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Australia; Precision Medicine, School of Clinical Sciences, Monash Health, Monash University, Clayton, Victoria, Australia.

Purpose: The incidence of renal cell carcinoma (RCC) is rising. Use of analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol may affect renal function. The aim of this study was to assess associations between analgesic use and risk of RCC. Read More

View Article and Full-Text PDF
September 2021

Low-grade Oncocytic Fumarate Hydratase-deficient Renal Cell Carcinoma: An Update on Biologic Potential, Morphologic Spectrum, and Differential Diagnosis With Other Low-grade Oncocytic Tumors.

Adv Anat Pathol 2021 Sep 27. Epub 2021 Sep 27.

Department of Pathology and Laboratory Medicine, University of Kansas School of Medicine, Kansas City, KS Department of Pathology, University of Utah and ARUP Laboratories, Salt Lake City, UT Departments of Pathology and Urology, Virginia Commonwealth University, School of Medicine, Richmond, VA Department of Pathology and Laboratory Medicine, University of Tennessee Health Sciences, Memphis, TN Department of Urology, USC Keck School of Medicine, Los Angeles, CA.

Fumarate hydratase-deficient renal cell carcinoma (FH-deficient RCC) is typically considered a high-grade, aggressive subtype of RCC that frequently arises in the setting of hereditary leiomyomatosis-renal cell carcinoma (HLRCC) syndrome. Increasing experience with HLRCC-associated RCC and FH-deficient RCC has resulted in recognition of tumors with lower grade morphologic features, overlapping with those of succinate dehydrogenase-deficient RCC and other low-grade oncocytic tumors. In this review article, we report a previously unpublished case that was recently encountered in our practice and review cases in the current literature with an aim of getting a better understanding of these oncocytic tumors and their morphologic spectrum. Read More

View Article and Full-Text PDF
September 2021

Clinical Importance of Plasma Drug Concentration of Oral Molecular Targeted Drugs for Renal Cell Carcinoma.

J Pharm Pharm Sci 2021 ;24:127-136

Department of Pharmaceutical Sciences, Tohoku University Hospital, Miyagi.

Purpose: Therapeutic drug monitoring (TDM) is widely used in clinical practice to maximize drug efficacy and minimize toxicities. Currently, it is also practiced in the use of oral molecular targeted drugs. The objective of this study was to assess the clinical importance of measuring the systemic concentration of oral molecular targeted drugs used to treat renal cell carcinoma (RCC). Read More

View Article and Full-Text PDF
January 2021

SDHC phaeochromocytoma and paraganglioma: A UK-wide case series.

Clin Endocrinol (Oxf) 2021 Sep 24. Epub 2021 Sep 24.

Department of Clinical Genetics, Birmingham Women's Hospital, Birmingham, UK.

Objective: Phaeochromocytomas and paragangliomas (PPGL) are rare, but strongly heritable tumours. Variants in succinate dehydrogenase (SDH) subunits are identified in approximately 25% of cases. However, clinical and genetic information of patients with SDHC variants are underreported. Read More

View Article and Full-Text PDF
September 2021

A rapid progression of new metastatic lesion after cytoreductive nephrectomy: A case report.

Urol Case Rep 2021 Nov 10;39:101848. Epub 2021 Sep 10.

Urology Department, Hasan Sadikin Academic Medical Center, Universitas Padjadjaran, Bandung, Indonesia.

A 55-years-old man presented with the chief complaint of right flank mass and hematuria. CT scan revealed clinical T4 RCC. Cytoreductive nephrectomy (CN) was performed with histopathology result of Papillary renal cell carcinoma. Read More

View Article and Full-Text PDF
November 2021

Prognostic significance of extent of venous tumor thrombus in patients with non-metastatic renal cell carcinoma: Results from a Canadian multi-institutional collaborative.

Urol Oncol 2021 Sep 20. Epub 2021 Sep 20.

Section of Urology, University of Manitoba, Winnipeg, Manitoba, Canada. Electronic address:

Purpose: The prognostic significance of level of venous tumor thrombus (VTT) extension in patients with non-metastatic renal cell carcinoma (RCC) has been controversial. The aim of this study was to examine the prognostic significance of VTT extent in patients who underwent surgery for non-metastatic RCC.

Materials And Methods: The Canadian Kidney Cancer information system database was used to identify patients who underwent surgery for non-metastatic RCC and VTT from January 2011 to December 2019. Read More

View Article and Full-Text PDF
September 2021

Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway.

J Hematol Oncol 2021 Sep 23;14(1):152. Epub 2021 Sep 23.

Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing, 210023, China.

Chimeric antigen receptor T-cell (CAR-T) therapy has shown tremendous success in eradicating hematologic malignancies. However, this success has not yet been extrapolated to solid tumors due to the limited infiltration and persistence of CAR-T cells in the tumor microenvironment (TME). In this study, we screened a novel anti-CD70 scFv and generated CD70 CAR-T cells that showed effective antitumor functions against CD70 renal carcinoma cells (RCCs) both in vitro and in vivo. Read More

View Article and Full-Text PDF
September 2021

Inhibition of FSTL3 abates the proliferation and metastasis of renal cell carcinoma via the GSK-3β/β-catenin signaling pathway.

Aging (Albany NY) 2021 Sep 23;13(undefined). Epub 2021 Sep 23.

Department of Urology, Zaozhuang Municipal Hospital, Zaozhuang 277100, Shandong, China.

Renal cell carcinoma (RCC) is a lethal malignancy of the genitourinary system. Follistatin-like 3 (FSTL3), which mediates cell differentiation and growth, acts as a biomarker of tumors and participates in cancer development and progression. Presently, the FSTL3's functions in RCC were investigated. Read More

View Article and Full-Text PDF
September 2021

Postoperative Aortic Regurgitation in Outflow Ventricular Septal Defect: Determinants of Outcome.

Semin Thorac Cardiovasc Surg 2021 Sep 20. Epub 2021 Sep 20.

Senior Professor, and former head, Department of cardiology, Sree Chitra Tirunal Institute of medical sciences and technology, Thiruvananthapuram, Kerala, India, 695011. Electronic address:

Aortic cusp prolapse is an acquired complication and usually precedes the development of aortic regurgitation (AR) in unoperated outflow ventricular septal defect (VSD). However, its impact on postoperative AR-progression is unknown. 161 patients with outflow-VSD and AR who underwent surgery between 2006 and 2012 were studied retrospectively. Read More

View Article and Full-Text PDF
September 2021

Outcome of laparoscopic nephron sparing surgery using a Satinsky clamp for hilar control: a trusted tool (SKIMS experience).

Curr Urol 2021 Sep 20;15(3):172-175. Epub 2021 May 20.

Department of Urology, Sheri Kashmir Institute of Medical Sciences, Soura, Srinagar, Jammu and Kashmir, India.

Background: Nephron sparing surgery is a well-established surgical procedure for patients with small/bilateral renal masses. During the procedure, hilar control can be achieved by using bulldog clamps individually on the renal vessels, the renal artery alone without clamping the vein, or a laparoscopic Satinsky clamp for en bloc hilar clamping. In our series, we described the outcome of laparoscopic nephron sparing surgery using a Satinsky clamp for hilar control. Read More

View Article and Full-Text PDF
September 2021

Unusual endophytic non-enhancing tumour in the renal pelvis: a diagnostic dilemma.

BMJ Case Rep 2021 Sep 22;14(9). Epub 2021 Sep 22.

Histopathology, PGIMER, Chandigarh, Chandigarh, India.

Renal cell cancer (RCC) is incidentally detected on imaging in 50%-60% of cases. Among the RCCs, clear cell variant is most common and classically seen as heterogenous enhancing lesion on CT imaging. Hypoenhancing mass presents a diagnostic dilemma with differential diagnosis being urothelial carcinoma, fat poor angiomyolipoma, oncocytoma or rarer variants of RCC. Read More

View Article and Full-Text PDF
September 2021

Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma.

Clin Cancer Res 2021 Sep 22. Epub 2021 Sep 22.

Department of Internal Medicine, The University of Texas Southwestern Medical Center.

Purpose: This phase II clinical trial evaluated whether the addition of stereotactic radiotherapy (SAbR), which may promote tumor antigen presentation, improves the overall response rate (ORR) to high-dose IL-2 (HD-IL-2), in metastatic renal cell carcinoma (mRCC).

Experimental Design: Patients with pathologic evidence of clear cell RCC and radiographic evidence of metastasis were enrolled in this single arm trial and were treated with SAbR, followed by HD-IL-2. ORR was assessed based on non-irradiated metastases. Read More

View Article and Full-Text PDF
September 2021

Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival.

Urol Oncol 2021 Sep 19. Epub 2021 Sep 19.

Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

Objective: Tumor shrinkage of at least 10% after presurgical targeted molecular therapy (TMT) in renal cell carcinoma (RCC) patients has been associated with better overall survival (OS) outcomes. We characterized primary and metastatic tumor diameter response and OS in patients with metastatic clear cell RCC (ccRCC) who received preoperative TMT, immunotherapy, or both followed by deferred cytoreductive nephrectomy (dCN).

Materials And Methods: Patients with metastatic ccRCC (n = 198) who underwent preoperative therapy and dCN from 2005 to 2019 were identified retrospectively. Read More

View Article and Full-Text PDF
September 2021

Understanding the research capacity and culture of a regional allied health workforce.

Aust J Prim Health 2021 Sep 23. Epub 2021 Sep 23.

The aim of this study was to understand the research capacity and culture of a regional allied health workforce over time. A cross-sectional study design was used, with data collected using the validated Research Capacity and Culture (RCC) tool. The results were compared with an earlier administration of the RCC survey. Read More

View Article and Full-Text PDF
September 2021

PBRM1 loss in kidney cancer unbalances the proximal tubule master transcription factor hub to repress proximal tubule differentiation.

Cell Rep 2021 Sep;36(12):109747

Department of Translational Hematology & Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. Electronic address:

PBRM1, a subunit of the PBAF coactivator complex that transcription factors use to activate target genes, is genetically inactivated in almost all clear cell renal cell cancers (RCCs). Using unbiased proteomic analyses, we find that PAX8, a master transcription factor driver of proximal tubule epithelial fates, recruits PBRM1/PBAF. Reverse analyses of the PAX8 interactome confirm recruitment specifically of PBRM1/PBAF and not functionally similar BAF. Read More

View Article and Full-Text PDF
September 2021

[Eosinophilic, solid, and cystic renal cell carcinoma (ESC-NZK)].

Pathologe 2021 Sep 22. Epub 2021 Sep 22.

Institut für Pathologie, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Krankenhausstraße 8-10, 91054, Erlangen, Deutschland.

Despite its descriptive name, eosinophilic, solid, and cystic renal cell carcinoma (ESC-RCC) represents a distinctive epithelial renal tumor entity defined by characteristic clinicopathological and molecular features. ESC-RCC occurs predominantly in women and is characterized in the majority of cases by sporadic (somatic) TSC mutations. A small subset of cases, however, affects patients with TSC germline mutations (tuberous sclerosis syndrome). Read More

View Article and Full-Text PDF
September 2021

Dynamic biomarker and imaging changes from a phase II study of pre- and post-surgical sunitinib.

BJU Int 2021 Sep 22. Epub 2021 Sep 22.

Cambridge University Hospitals NHS Foundation Trust, Department of Oncology, Box 193, Hills Road, Cambridge, CB2 0QQ, UK.

Objective: To explore translational biological and imaging biomarkers for Sunitinib treatment prior to and after debulking nephrectomy.

Methods: Treatment-naïve patients with metastatic renal cell carcinoma (mRCC) received 50mg OD Sunitinib for 12 days pre-surgically, then post-surgery on 4 week-on, 2 week-off, repeating 6 week cycles until disease progression in a single arm phase II trial. Structural and dynamic contrast-enhanced MR imaging (DCE-MRI) and research blood sampling were performed at baseline and after 12 days. Read More

View Article and Full-Text PDF
September 2021

Incidental occurrence of papillary renal cell carcinoma in the native kidney with autosomal dominant polycystic kidney disease after renal transplantation: A case report.

Mol Clin Oncol 2021 Nov 31;15(5):223. Epub 2021 Aug 31.

Institute of Pathology and Cytology, D-48465 Schüttorf, Germany.

Autosomal dominant polycystic kidney disease (ADPKD) is one of the best-known genetic diseases. Almost half of the patients with ADPKD will develop end-stage renal disease, and the majority of patients are treated with renal transplantation. The current study presents a case that developed papillary renal cell carcinoma (PRCC) in the native right kidney 10 years after renal transplantation. Read More

View Article and Full-Text PDF
November 2021

Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy.

Nat Commun 2021 Sep 20;12(1):5547. Epub 2021 Sep 20.

Department of Urology, Keio University School of Medicine, 160-8582, Tokyo, Japan.

A cutting edge therapy for future immuno-oncology is targeting a new series of inhibitory receptors (IRs): LAG-3, TIM-3, and TIGIT. Both immunogenomic analyses and diagnostic platforms to distinguish candidates and predict good responders to these IR-related agents are vital in clinical pathology. By applying an automated single-cell count for immunolabelled LAG-3, TIM-3, and TIGIT, we reveal that individual IR levels with exclusive domination in each tumour can serve as valid biomarkers for profiling human renal cell carcinoma (RCC). Read More

View Article and Full-Text PDF
September 2021

Elongin functions as a loading factor for Mediator at ATF6α-regulated ER stress response genes.

Proc Natl Acad Sci U S A 2021 09;118(39)

Stowers Institute for Medical Research, Kansas City, MO 64110;

The bZIP transcription factor ATF6α is a master regulator of endoplasmic reticulum (ER) stress response genes. In this report, we identify the multifunctional RNA polymerase II transcription factor Elongin as a cofactor for ATF6α-dependent transcription activation. Biochemical studies reveal that Elongin functions at least in part by facilitating ATF6α-dependent loading of Mediator at the promoters and enhancers of ER stress response genes. Read More

View Article and Full-Text PDF
September 2021

USP39 promotes malignant proliferation and angiogenesis of renal cell carcinoma by inhibiting VEGF-A alternative splicing via regulating SRSF1 and SRPK1.

Cancer Cell Int 2021 Sep 20;21(1):486. Epub 2021 Sep 20.

Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, 1665 Kongjiang Road, Shanghai, 200092, China.

Background: The benefit of targeted therapy for renal cell carcinoma (RCC) is largely crippled by drug resistance. Rapid disease progression and poor prognosis occur in patients with drug resistance. New treatments demand prompt exploration for clinical therapies. Read More

View Article and Full-Text PDF
September 2021

Esophageal metastasis of renal cell carcinoma resected by endoscopic submucosal dissection: a case report.

BMC Gastroenterol 2021 Sep 20;21(1):348. Epub 2021 Sep 20.

Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki, Japan.

Background: Esophageal metastasis of renal cell carcinoma (RCC) is extremely rare. We have described herein a case of a 59-year-old man with esophageal metastasis of RCC that was endoscopically resected.

Case Presentation: The case was a 59-year-old man who had undergone left nephrectomy for renal clear cell carcinoma 17 years ago and splenectomy for splenic metastasis 3 years ago. Read More

View Article and Full-Text PDF
September 2021

On normalizing of urinary KIM-1 level to urine creatinine in patients with renal cell cancer.

Klin Lab Diagn 2021 Sep;66(9):517-524

Federal State Budgetary Institution "National Medical Research Radiological Centre", Ministry of Health of the Russian Federation.

KIM-1 (kidney injury molecule 1), a marker of acute kidney injury, is produced by epithelial cells of renal proximal tubules. Elevated KIM-1 levels in urine and plasma are associated with renal cell carcinoma (RCC). The aim of this study was to compare the significance of non-normalized uKIM-1 values and those normalized to urine creatinine, as urinary biomarkers in RCC. Read More

View Article and Full-Text PDF
September 2021

Comparison of Sutureless Suture Partial Nephrectomy for Clinical T1 Renal Cell Carcinoma: A Meta-Analysis of Retrospective Studies.

Front Oncol 2021 2;11:713645. Epub 2021 Sep 2.

Department of Urology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.

Background: Partial nephrectomy (PN) is the recommended treatment for T1 renal cell carcinoma (RCC). Compared with suture PN, sutureless PN reduces the difficulty and time of operation, but the safety and feasibility have been controversial. This meta-analysis was conducted to compare the function and perioperative outcomes of suture and sutureless PN for T1 RCC. Read More

View Article and Full-Text PDF
September 2021

Recurrence Risk of Renal Cell Carcinoma Lingers Even Decades After Nephrectomy.

Cureus 2021 Aug 16;13(8):e17217. Epub 2021 Aug 16.

Oncology, Atomic Energy Cancer Hospital (NORI), Islamabad, PAK.

Renal cell carcinoma (RCC) is a common malignancy in elderly males. Metastatic spread of this cancer is not an uncommon occurrence, even after nephrectomy. Lung, bone, liver, and brain are the most frequently involved sites. Read More

View Article and Full-Text PDF

Efficacy of Enhanced Cytokine-Induced Killer Cells as an Adjuvant Immunotherapy for Renal Cell Carcinoma: Preclinical and Clinical Studies.

J Healthc Eng 2021 8;2021:5709104. Epub 2021 Sep 8.

Central Laboratory of Yan'an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan Province, China.

Cytokine-induced killer (CIK) cells have been proved to be an effective method of tumor immunotherapy in numerous preclinical and clinical studies. In our previous study, a new method was developed to prime and propagate CIK cells by the combination of IL-2 and IL-15, and this kind of CIK cells had enhanced antitumor effect on lung cancer. For renal cell carcinoma (RCC), immunotherapy plays an important role because of the poor efficacy of radiotherapy and chemotherapy. Read More

View Article and Full-Text PDF
September 2021

TFEB promotes BCL-2 expression by upregulating its promoter activity in the t(6;11) translocation renal cell carcinomas.

Am J Transl Res 2021 15;13(8):8804-8818. Epub 2021 Aug 15.

Institute of Clinical Virology, Anhui Medical University Hefei 230032, Anhui, China.

t(6;11) translocation renal cell carcinoma (RCC) is classified as a subset of the MiT family translocation RCCs and characterized by harboring the Alpha-TFEB fusion gene. However, the development mechanism of this tumor and its effective treatment have not been fully identified yet. The purpose of this study was to explore the relationship between TFEB and BCL-2 in Alpha-TFEB stably transfected cell lines and in t(6;11) RCC tumor tissue. Read More

View Article and Full-Text PDF

Impact of a relationship-centered care communication curriculum on pediatric residents' practice, perspectives, and opportunities to evelop expertise.

Patient Educ Couns 2021 Sep 9. Epub 2021 Sep 9.

Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA. Electronic address:

Objectives: To investigate the impacts of a Relationship-Centered Care (RCC) communication curriculum with coaching on pediatric residents 1) self-reported use of RCC strategies and perspectives, and 2) opportunities to develop adaptive expertise.

Methods: Residents (n = 77) completed a 4 h RCC training and shared resultant RCC goals with Coaches (n = 15). Data included resident surveys and reflections immediately post-training, and resident and coach surveys 6-months later. Read More

View Article and Full-Text PDF
September 2021

RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.

Contemp Clin Trials 2021 Sep 16;108:106482. Epub 2021 Sep 16.

MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, 2nd Floor 90 High Holborn, London WC1V 6LJ, UK.

Background: 20-60% of patients with initially locally advanced Renal Cell Carcinoma (RCC) develop metastatic disease despite optimal surgical excision. Adjuvant strategies have been tested in RCC including cytokines, radiotherapy, hormones and oral tyrosine-kinase inhibitors (TKIs), with limited success. The predominant global standard-of-care after nephrectomy remains active monitoring. Read More

View Article and Full-Text PDF
September 2021